Prospect News: News for CuraGen Corp.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Price: $0.00

Account balance: $0.00

Add to balance / Manage account

User: lxbfYeaa

Log out

Prospect News home > Main news index > All issuers starting with C > All stories on CuraGen Corp.

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

CuraGen Corp.

12/31/2009	CV	Celldex assumes obligations of CuraGen's 4% convertibles after merger
10/2/2009	CV	CuraGen amends indenture of 4% convertibles following Celldex merger
10/2/2009	SS	CuraGen becomes wholly owned subsidiary of Celldex Therapeutics
8/28/2009	SS	Celldex Therapeutics, CuraGen shareholders to vote on merger Sept. 30
7/31/2009	CV	CuraGen buys back $1.64 million 4% convertibles subordinated notes
6/22/2009	SS	CuraGen investor DellaCamera sells shares, cuts ownership to 4.5%
5/29/2009	SS	Market Commentary: AOL to add board within months; Celldex gains CuraGen cash; FiberNet counter bid predicted
5/14/2008	CV	CuraGen buys back $50.9 million of 4% convertibles
11/15/2007	CV	CuraGen buys back $22.2 million 4% convertibles
3/29/2007	SS	Market Commentary: Lone Star deal propels Ipsco, others; Tribune rises; Riviera recoils; IMAX off; CuraGen dives
10/26/2006	BT	CuraGen to make development decisions on lead products in 2007
8/24/2006	BT	CuraGen, TopoTarget: Southwest Oncology Group starts lymphoma trial
8/10/2006	BT	CuraGen, TopoTarget begin phase 1 trial for using oral PXD101 to treat solid tumors
8/8/2006	BT	CuraGen, TopoTarget start PXD101 and azacitidine trial to treat blood cancers
7/27/2006	BT	CuraGen reports second-quarter net loss of $14.3 million
7/19/2006	BT	CuraGen to receive royalties on Bayer's licensing of BAY 76-7171 for diabetes management
7/14/2006	BT	CuraGen, TopoTarget begin phase 1/ 2 trial of PXD101 for liver cancer
6/26/2006	BT	CuraGen: New method can detect cancer gene mutations at low levels
6/22/2006	BT	CuraGen begins phase 1 trial with CR011-vcMMAE for metastatic melanoma
6/22/2006	BT	CuraGen says it will select drug candidates for regulatory development by end of 2007
6/20/2006	BT	CuraGen, TopoTarget begin patient dosing in phase 2 trial of PXD101 for treatment of mesothelioma
6/14/2006	BT	CuraGen, TopoTarget begin phase 1 trial of PXD101, cis-retinoic acid in solid tumors
6/6/2006	BT	CuraGen, TopoTarget start phase 2 trial of PXD101 for acute myelogenous leukemia
5/30/2006	BT	CuraGen starts second phase 2 velafermin trial
5/19/2006	CV	Market Commentary: SafeNet improves dollar-neutral on federal probe; American Axle likely to be converted, analyst says
4/26/2006	BT	CuraGen, Roche Diagnostics launch updated version of the Genome Sequencer 20 System
4/6/2006	BT	CuraGen, TopoTarget present preclinical data on PXD101 at the AACR meeting
3/29/2006	BT	CuraGen, TopoTarget begin clinical trial with PXD101 to treat tumors, lymphoma
3/22/2006	BT	CuraGen, TopoTarget starts phase 1b/2 trial of PXD101 and Velcade to treat blood cancer
2/21/2006	BT	Further data from CuraGen's phase 2 trial on velafermin show efficacy at lowest dose
2/21/2006	BT	Market Commentary: Alnylam up 10% on Novartis pact; OSI off; CuraGen clipped; Inspire comes in; Ista drops despite data
2/6/2006	BT	Market Commentary: OSI Pharma players debate new policy; Serono slips as 'for sale' sign stands; CuraGen gains 11%
2/1/2006	BT	CuraGen, TopoTarget begin phase 2 clinical trial of PXD101 for lymphoma
12/20/2005	BT	CuraGen opts for tiered royalties, drops development costs in Bayer collaboration
12/20/2005	BT	Market Commentary: Connetics rebounds to end higher; SeraCare plunges 48%; OraSure gains 8%; CuraGen rises by 4%
12/13/2005	BT	CuraGen tests show velafermin reduces oral mucositis, but tests not statistically significant
12/13/2005	BT	Market Commentary: CuraGen sinks; Indevus soars; Voyager pulls IPO; Insmed up on FDA approval; Tercica falls
12/13/2005	CV	Market Commentary: Omnicare edges higher; Intel, Ceradyne on deck; price talk emerges on Entergy mandatories
12/12/2005	BT	CuraGen, TopoTarget says PXD101 well tolerated, shows potential activity in phase 1 trial
11/18/2005	BT	CuraGen, TopoTarget PXD101 well tolerated, shows some antitumor activity as single agent
11/14/2005	BT	CuraGen says CR002 phase 1 study shows potential to treat kidney inflammation associated with PDGF-D
9/20/2005	BT	Market Commentary: Cyberonics convertible view mixed; Human Genome rises on update; Alkermes, Cephalon off on delay
9/20/2005	BTCV	CuraGen buys back $23.9 million 6% convertibles
9/8/2005	CV	Market Commentary: Convertibles trade mixed, with Amgen, Nabors edging up, Cypress Semiconductor down
9/6/2005	CV	Market Commentary: Chiron trades mixed, but Curagen gains; Dobson Communications to price $150 million issue
8/10/2005	BT	New Issue: CuraGen raises $22 million in follow-on at $5.50, discounted from $6.06 close
8/10/2005	BT	Market Commentary: Coley, China Medical IPOs zoom out of gate; CuraGen off due to follow-on; Electro-Optical on hold
8/10/2005	CV	CuraGen to repurchase convertibles using stock offering proceeds
7/25/2005	BTCV	CuraGen buys back $39.9 million 6% convertibles due 2007 for $37.7 million
7/8/2005	CV	Market Commentary: Biotechs, chips lead convertibles mostly higher; Charming Shoppes, Henry Schein trade higher
5/12/2005	CV	Market Commentary: GM, Ford head renewed move south; Delta convertibles idle after 7.7s swapped for equity
4/26/2005	CV	Market Commentary: Curagen plunges amid big sellout; Level 3 founders; XM rises, Sirius dips; Wynn bid up; airlines plunge
3/15/2005	CV	Market Commentary: Central Parking up; Whole Foods off as Wild Oats rises; Ivax better, Curagen slides; Leucadia easier
10/19/2004	CV	Market Commentary: Delta convertibles dive 1 point each; Jakks Pacific slammed by lawsuit; Ford, GM off
10/13/2004	CV	Market Commentary: Delta convertibles rise sharply; Amkor buyers heartened; Lucent edges up, Apex easier
4/27/2004	CV	Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
3/16/2004	CV	CuraGen greenshoe partially exercised, raising convertibles to $110 million
2/12/2004	CVDD	S&P rates CuraGen converts CCC
2/11/2004	CV	New Issue: CuraGen upsized $100 million convertible yields 4.0%, up 37%
2/11/2004	CV	Market Commentary: Disney steals show; Echostar cast as takeover target, too; Safeguard advanced
2/10/2004	CV	Market Commentary: New deals active; Solectron loses 0.5 point; AMR reoffered at 98.5; CuraGen, InterMune ahead
2/9/2004	CV	CuraGen $75 million convertible talked at 3.75-4.25% yield, up 33-37%
2/9/2004	CV	Market Commentary: Calpine 4s add 1.25 points on tender; Juniper whacked 11.25 points; four deals tossed to market
11/10/2003	CV	Market Commentary: Biotech paper grabs attention as yield-hungry investors invade market

©2026 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.